Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1613103/000161310322000023/mdt-20220429.htm
March 2023
March 2023
February 2023
December 2022
November 2022
September 2022
August 2022
June 2022
May 2022
May 2022
Contacts: | ||||||||||||||
Erika Winkels | Ryan Weispfenning | |||||||||||||
Public Relations | Investor Relations | |||||||||||||
+1-763-526-8478 | +1-763-505-4626 |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1613103/000161310322000023/mdt-20220429.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Medtronic Plc.
Medtronic Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
Financing Activities The $1.2 billion increase in net cash used was largely the result of the increase of share repurchases of $1.9 billion.
The following is a summary of other costs and expenses (income): Amortization of Intangible Assets Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of purchased patents, trademarks, tradenames, customer relationships, purchased technology, and other intangible assets.
Looking ahead, a number of macro-economic and geopolitical factors could negatively impact our business, including without limitation: The uncertain and uneven impact of COVID-19 on future procedural volumes, supply constraints including certain electronic components and semiconductors, healthcare staffing, worker absenteeism with our customers, suppliers, and in our own operations and field teams, and resulting impacts on demand for our products and therapies; The potential impact that sanctions and other measures being imposed in response to the Russia-Ukraine conflict could have on revenue and supply chain.
RGR net sales declines were largely due to declines in ventilator demands when compared fiscal year 2021 as demand returned to pre-pandemic levels in the fourth quarter of fiscal year 2022.
LIQUIDITY AND CAPITAL RESOURCES We are currently in a strong financial position, and we believe our balance sheet and liquidity as of April 29, 2022 provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs.
(6)The net benefit primarily relates...Read more
Because the effective rate can...Read more
For fiscal years 2022 and...Read more
Investing Activities The $1.2 billion...Read more
For fiscal years 2022 and...Read more
Looking forward, our cost of...Read more
Most of our businesses were...Read more
The operational tax benefits included...Read more
The charges included $515 million...Read more
Estimating probable losses from our...Read more
The net sales increase was...Read more
The decrease in interest expense...Read more
The net sales increase was...Read more
Certain Litigation Charges We classify...Read more
Net sales growth was primarily...Read more
The charges of $823 million...Read more
The net sales increase was...Read more
Diabetes' net sales decline for...Read more
Cardiac Surgery also contributed to...Read more
Net sales growth was driven...Read more
Cash paid to employees increased...Read more
The increase was led by...Read more
Net sales growth was led...Read more
The decrease in other non-operating...Read more
Beyond the contractual obligations and...Read more
The increase in net cash...Read more
Continued acceptance and growth of...Read more
Summary of Cash Flows The...Read more
The decrease in cost of...Read more
Since inception, the Company has...Read more
In the normal course of...Read more
Net sales growth was primarily...Read more
ENT growth was driven by...Read more
Cardiac Ablation Solutions also led...Read more
Market acceptance and growth from...Read more
(1)Associated costs include costs incurred...Read more
The estimates could be impacted...Read more
The increase was led by...Read more
Cardiovascular Cardiovascular products include pacemakers,...Read more
Although the implications of this...Read more
Our investments primarily include available-for-sale...Read more
In total, the Company estimates...Read more
In total, the Company estimates...Read more
Growth in the broader vertebral...Read more
The tables below present reconciliations...Read more
Currency had an unfavorable impact...Read more
Currency had an unfavorable impact...Read more
Currency had an unfavorable impact...Read more
We believe our balance sheet...Read more
Refer to the "GAAP to...Read more
In addition to the macro-economic...Read more
Competitive product launches and pricing...Read more
Although we believe that we...Read more
We believe our off-balance sheet...Read more
Income Tax Reserves We establish...Read more
The Company used the net...Read more
In addition to the macro-economic...Read more
In addition to the macro-economic...Read more
Interest Expense Interest expense includes...Read more
This growth was partially offset...Read more
Pelvic Health's growth was led...Read more
Neurovascular's growth was led by...Read more
Intangible assets primarily include patents,...Read more
The summarized results of operations...Read more
Sales growth occurred in both...Read more
Other Non-Operating Income, Net Other...Read more
Determining the fair value of...Read more
NEW ACCOUNTING PRONOUNCEMENTS Information regarding...Read more
A benefit of $82 million...Read more
Growth in CST also occurred...Read more
Total consideration for the transaction...Read more
Finally, contributing to the change...Read more
Medical Surgical's net sales for...Read more
Neuroscience's net sales for fiscal...Read more
Cardiovascular net sales for fiscal...Read more
Our earnings in Puerto Rico...Read more
The charts below illustrate the...Read more
The graphs below illustrate the...Read more
Specialty Therapies (Specialty) net sales...Read more
Neuromodulation (NM) net sales for...Read more
The charts below illustrate the...Read more
Structural Heart & Aortic (SHA)...Read more
Coronary & Peripheral Vascular (CPV)...Read more
CRITICAL ACCOUNTING ESTIMATES We have...Read more
Respiratory, Gastrointestinal, & Renal (RGR)...Read more
We also test definite-lived intangible...Read more
We assess the impairment of...Read more
We use estimates that are...Read more
We reevaluate the technical merits...Read more
In addition to the macro-economic...Read more
Continued acceptance and growth of...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Medtronic Plc provided additional information to their SEC Filing as exhibits
Ticker: MDT
CIK: 1613103
Form Type: 10-K Annual Report
Accession Number: 0001613103-22-000023
Submitted to the SEC: Thu Jun 23 2022 4:13:25 PM EST
Accepted by the SEC: Thu Jun 23 2022
Period: Friday, April 29, 2022
Industry: Electromedical And Electrotherapeutic Apparatus